Surrey Heartlands

Joint Formulary & PAD

Lecanemab - Alzheimers disease

You are here : Home > Formulary Search > Lecanemab - Alzheimers disease

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

See narrative
Formulations :
  • Intravenous infusion
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NFD2
Restrictions / Comments :
Important

Lecanemab used in Alzheimer’s disease is currently not available in the NHS. Eisai (the manufacturer and market authorisation holder for lecanemab (Leqembi®)) has started to make the drug available for patients to access through independent sector clinics.
 

The information from NHSE here provides advice for clinical teams who may be asked to support referrals for private treatment or otherwise assess, advise and possibly treat a small number of patients who could present with potential adverse treatment effects, including symptomatic Amyloid-Related Imaging Abnormalities (ARIA).

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Lecanemab
Indication :
Alzheimers disease
Group Name :
Keywords :
Brand Names Include :
Leqembi
Important Information :
Important safety information - see narrative by clicking on the drug name
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Lecanemab is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Alzheimers disease.

Committee Recommendations (1)

04 Dec 24 - Not Set

Lecanemab used in Alzheimer’s disease is currently not available in the NHS. Eisai (the manufacturer and market authorisation holder for lecanemab (Leqembi®)) has started to make the drug available for patients to access through independent sector clinics.
 

The information from NHSE here provides advice for clinical teams who may be asked to support referrals for private treatment or otherwise assess, advise and possibly treat a small number of patients who could present with potential adverse treatment effects, including symptomatic Amyloid-Related Imaging Abnormalities (ARIA).

NICE are due to publish guidance on this drug in February 2025 and this will be considered by the APC within 90 days of publication.